https://www.templehealth.org/about/news/excision-biotherapeutics-secures-60-million-to-advance-crispr-based-gene-editing-constructs-developed-at-temple-into-clinical-trial-for-people-living-with-chronic-hiv-infection
The funding will allow these treatments to be advanced into a Phase 1/2 clinical trial in patients with chronic HIV infection. The funding secured by Excision will also provide Temple scientists and Excision the ability to research CRISPR technology on other viral diseases at LKSOM including JC Virus for Progressive Multifocal ...